Nahm CB, et al. - Considering their recently published systematic review of prognostic immunohistochemical biomarkers in pancreatic ductal adenocarcinoma (PDAC) enlisting a panel of those reported with the highest level of evidence, including p53, p16, Ca-125, S100A4, FOXC1, EGFR, mesothelin, CD24 and UPAR, researchers sought to discover and validate the prognostic significance of a combinatorial panel of tumor biomarkers in patients with resected PDAC. The discovery and validation cohorts comprised 224 and 191 patients, respectively. Outcomes suggest that survival after resection of localized PDAC could be stratified using the combinations of S100A4, Ca-125 and mesothelin expression. The poorest prognostic outcome was evident in relation to co-expression of all three biomarkers.